Eculizumab, a monoclonal antibody that blocks C5 activation, has demonstrated potential in reducing complement-mediated damage in conditions like paroxysmal nocturnal hemoglobinuria (PNH) [52]. The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.